Skip to content

Industry Research Report on the Pharmaceuticals in Brazil.

Value Chain outline

The pharmaceutical industry value chain in Brazil is a complex system encompassing several interconnected stages, from the research and development of new drugs and the production of active pharmaceutical ingredients (APIs) and finished products, through distribution networks, to the final point of sale to the consumer or healthcare institutions. The chain is significantly influenced by stringent regulations, market dynamics, and the interplay between national and multinational players.

Identification and description of each step in the value chain

The main steps in the pharmaceutical value chain in Brazil can be broadly identified as:

  1. Input Production (Farmoquímica): This initial stage involves the synthesis of active pharmaceutical ingredients (IFAs) and excipients.
  2. Pharmaceutical Production: This step focuses on formulating, manufacturing, testing, and packaging the finished medicinal products using IFAs and excipients.
  3. Distribution: This stage involves the logistics and transportation of finished pharmaceutical products from manufacturers to various points of sale and healthcare facilities.
  4. Retail and Commercialization: This final step encompasses the sale of medicines and other health-related products directly to the end consumer or institutions.

Identification and description of segments for each step of the value chain.

  • Input Production (Farmoquímica):

    • Segments: Production of Active Pharmaceutical Ingredients (IFAs), Production of Excipients.
    • Description: This segment is characterized by complex chemical synthesis processes, often involving multiple intermediate steps. It provides the fundamental components necessary for drug manufacturing. A significant challenge in Brazil is the high dependence on imported IFAs.

  • Pharmaceutical Production:

    • Segments: Research and Development (R&D), Manufacturing of Innovative Medicines, Manufacturing of Generics, Manufacturing of Similar Medicines, Manufacturing of Biologics/Biosimilars, Manufacturing of Fitoterapics, Manufacturing of Manipulated Medicines.
    • Description: This stage includes discovering new molecules through extensive R&D, conducting clinical trials, and scaling up production following strict Good Manufacturing Practices (BPF). The manufacturing segment is responsible for transforming IFAs and excipients into final dosage forms. Different segments cater to distinct market needs and regulatory pathways.

  • Distribution:

    • Segments: Wholesale Distribution (serving pharmacies, hospitals, clinics), Hospital Distribution (specialized in supplying healthcare institutions).
    • Description: Distributors act as intermediaries, receiving products from manufacturers and supplying them to points of sale and healthcare facilities. This involves warehousing, inventory management, and transportation under controlled conditions, especially for temperature-sensitive products. Strict regulations govern this stage to ensure product integrity and traceability.

  • Retail and Commercialization:

    • Segments: Large Pharmacy Chains, Associative and Independent Pharmacy Networks, Independent Pharmacies, Hospital Pharmacies, Public Health Posts (SUS).
    • Description: This is the point of direct interaction with the end consumer. Pharmacies and drugstores dispense medicines and other health/beauty products. Hospital pharmacies manage medication for inpatients and outpatients within a hospital setting. Public health posts provide access to essential medicines through the public healthcare system (SUS). The retail market is characterized by intense competition, particularly among large chains, and a growing trend towards offering a wider range of products and services beyond just medication.

List of types of players in each segment

  • Input Production (Farmoquímica):

    • Chemical and Farmoquímical Industries (national and international).
    • Specialized API manufacturers.

  • Pharmaceutical Production:

    • Multinational Pharmaceutical Companies (often focused on R&D and innovative medicines).
    • National Pharmaceutical Companies (active in generics, similars, and increasingly in R&D and complex molecules).
    • Biotechnology Companies.
    • Research Institutions and Universities.
    • Public Laboratories (e.g., Fiocruz, Butantan).
    • Contract Manufacturing Organizations (CMOs).

  • Distribution:

    • Wholesale Distributors (large national and regional players).
    • Specialized Distributors (e.g., hospitalar, specific product types).
    • Logistics Operators.

  • Retail and Commercialization:

    • Large Pharmacy Chains.
    • Associative Pharmacy Networks.
    • Independent Pharmacies.
    • Manipulation Pharmacies.
    • Hospital Pharmacies.
    • Public Health Units.
    • Online Pharmacies/E-commerce Platforms.

Detailed description of the main activities within each segment.

  • Input Production (Farmoquímica):

    • Synthesis of chemical compounds to produce Active Pharmaceutical Ingredients (IFAs).
    • Purification and quality control of IFAs and excipients.
    • Research and development of new synthesis routes.
    • Production of intermediate chemical products.

  • Pharmaceutical Production:

    • Research and Development (R&D): Discovery of new drug candidates, preclinical testing (laboratory and animal studies), and clinical trials (Phase I, II, III) to evaluate safety and efficacy in humans. This is a lengthy and costly process.
    • Manufacturing: Formulation of medicines (combining IFAs and excipients), large-scale production following strict Good Manufacturing Practices (BPF), quality control testing of raw materials, intermediate products, and finished goods.
    • Packaging and Labeling: Ensuring products are correctly packaged and labeled according to regulatory requirements.
    • Regulatory Affairs: Obtaining necessary registrations and approvals from ANVISA for production and commercialization.

  • Distribution:

    • Receiving and warehousing products from manufacturers under appropriate storage conditions (temperature, humidity).
    • Inventory management and order fulfillment.
    • Transportation of products to pharmacies, hospitals, and clinics across the country, adhering to specific transport regulations (e.g., RDC 430/2020 for temperature control).
    • Traceability of products within the supply chain.

  • Retail and Commercialization:

    • Dispensing of prescription and over-the-counter medications by qualified pharmacists.
    • Sale of a diverse range of health, hygiene, beauty, and wellness products.
    • Providing pharmaceutical services (e.g., vaccination, basic health checks, medication counseling).
    • Inventory management and purchasing from distributors or directly from manufacturers.
    • Marketing and sales activities, including loyalty programs and promotions.
    • Compliance with ANVISA regulations for retail establishments.

List examples of key players with detailed profiles.

Based on the provided context and search results for market share and ranking:

  • Grupo NC (includes EMS): A major Brazilian pharmaceutical group, leading in sales to pharmacies in Brazil in 2024 with R$ 26.4 billion in sales to pharmacies, showing a 9.6% growth in 2024. EMS is part of this group and is listed among the top Brazilian pharmaceutical companies.
  • Eurofarma: A significant pharmaceutical company in Brazil, it grew by 22.4% in revenue in 2024, achieving the second position in sales to pharmacies. It is also listed among the top Brazilian pharmaceutical companies.
  • Hypera Pharma: A prominent player, ranked third in sales to pharmacies in 2024 with 7.3% revenue growth. Hypera focuses on diversification, including specialty medicines and over-the-counter drugs (MIPs). It was also listed among the top Brazilian companies.
  • Novo Nordisk: A global pharmaceutical company with significant growth in Brazil (23.2% in 2024). It entered the top 3 in prescription medicine (Rx) sales in 2023, driven by diabetes medications.
  • RD Saúde (Raia Drogasil): The leading pharmacy chain group in Brazil, holding 28% of the main consumer market share among pharmacy chains in 2024. It had a revenue of R$ 3.6 billion in 2023 (ranking 4th among largest retailers overall) and shows high productivity per point of sale (R$ 12.3 million in 2023). RD Saúde was the leader in retail revenue for the 13th consecutive year in 2023.
  • Grupo DPSP (Drogaria São Paulo and Pacheco): A major pharmacy chain group, concentrating 11% of the main consumer market share among pharmacy chains in 2024. Ranked as the second largest network by revenue in 2023. It had a revenue of R$ 1.3 billion in 2023 (ranking 14th among largest retailers overall).
  • Grupo Pague Menos (Pague Menos and Extrafarma): Another significant pharmacy chain group, holding 11% of the main consumer market share among pharmacy chains in 2024. Ranked third by revenue in 2023 and second by number of stores. Showed significant growth in 2023 (13.5% sales increase for top networks). Pague Menos/Extrafarma had the highest growth among major retailers (21.82%) in 2023.
  • Other Key Players (Pharmaceutical Production/Rx Sales): Takeda, Bayer, Novartis, Aché, Sanofi, AstraZeneca were listed among the top 10 laboratories by Rx sales in Brazil in 2023. Aché is also a prominent national company. Multinational companies like Sanofi, Novartis, Pfizer, and Johnson & Johnson were also listed among the top groups in 2017.
  • Key Distributors: While specific distributor rankings by volume/value beyond their share in retail sales are less detailed in the provided sources, distributors are highlighted as crucial players, handling 57% of the volume and 55.7% of the value commercialized by retail in 2024. Abafarma represents distributors who were responsible for 68.8% of the value (R$ 60.8 billion) and 44.5% of the volume (2 billion units) moved by distributors in 2024. Examples mentioned include Grupo Palmed (regional presence) and Sulmedic (hospitalar distribution).

Show estimates of volumes and sizes of each step in the value chain.

Providing precise volume and size estimates for each specific step (Input Production, Production, Distribution, Retail) with granular detail for 2024/2025 is challenging based solely on the provided snippets, as data often overlaps or is presented for the overall market or specific segments like retail. However, based on the available information:

  • Overall Pharmaceutical Market in Brazil (2024): Estimated to have moved around R$ 220.9 billion, a growth of 12.7% compared to 2023. Another source indicates the sector's revenue should exceed US$ 20 billion in 2024. The retail pharmaceutical market alone reached R$ 158.4 billion in sales in 2024.
  • Input Production (Farmoquímica): Brazil imports about 90% of the raw materials (IFAs) used in medicine production. This highlights a significant volume of activity in this upstream segment, largely conducted internationally, with only 5% of insumos produced domestically.
  • Pharmaceutical Production: While a total production volume in units for the entire industry is not explicitly stated for 2024/2025, the retail sales volume provides an downstream indicator.
  • Distribution: Distributors handled 57% of the volume (4.6 billion units) and 55.7% of the value (R$ 88.3 billion) commercialized by retail in 2024. Abafarma members specifically accounted for R$ 60.8 billion in value and 2 billion units in volume within the distribution channel in 2024.
  • Retail and Commercialization (2024):
    • Total Sales Value: R$ 158.4 billion (at Pharmacy Purchase Price - PPP).
    • Total Sales Volume: 8.1 billion units. This was a 6.1% increase in volume compared to 2023 (7.6 billion units).
    • Number of Pharmacies/Drugstores: 93,700 establishments in activity in 2024.
    • Market Share (Retail Chains): The top three groups (RD Saúde, Grupo Pague Menos, Grupo DPSP) concentrate around 40% of the main consumers. The 29 large networks associated with Abrafarma represented over 47% of the retail pharmaceutical revenue up to September 2024.

Value Chain Summary Table

Value Chain Step Main Activities Segments Types of Players Estimated Volumes/Sizes (2024)
Input Production Chemical synthesis, purification, quality control of IFAs and excipients. IFA Production, Excipient Production. Chemical/Farmoquímical Industries, Specialized API Manufacturers. Brazil imports ~90% of IFAs. 5% domestic production.
Pharmaceutical Production R&D, formulation, manufacturing (BPF), quality control, packaging, regulatory affairs. R&D, Innovative Medicines, Generics, Similars, Biologics/Biosimilars, Fitoterapics, Manipulated. Multinational Pharma, National Pharma, Biotech, Research Institutions, Public Labs, CMOs. Overall market ~R$ 220.9 billion (potentially including non-retail). US$ 20+ billion (revenue). Production volume not explicitly detailed for 2024.
Distribution Warehousing, inventory, transportation (controlled conditions), traceability. Wholesale Distribution, Hospital Distribution. Wholesale Distributors (national/regional), Specialized Distributors, Logistics Operators. Handled 57% volume (4.6 billion units) and 55.7% value (R$ 88.3 billion PPP) of retail sales. Abafarma members: R$ 60.8 billion, 2 billion units.
Retail & Commercialization Dispensing medicines, sales (medicines, non-medicines), pharmaceutical services, inventory, marketing. Large Chains, Associative Networks, Independent Pharmacies, Hospital Pharmacies, Public Health Units, Online. Pharmacy Chains (national/regional), Independent Pharmacists, Hospitals, Government (SUS). Total Sales Value: R$ 158.4 billion (PPP). Total Sales Volume: 8.1 billion units. ~93.7k establishments. Top 3 chains ~40% consumer share. Abrafarma networks >47% revenue.

Examples of Main Players:

  • Grupo NC (includes EMS) (Pharmaceutical Production): As the leading national pharmaceutical group by sales to pharmacies in 2024, Grupo NC, with its flagship company EMS, plays a crucial role in the Brazilian market. They are significant manufacturers of generic and similar medicines, contributing to broader access to treatments. Their business model focuses on high volume production and a strong presence in the retail market.
  • Eurofarma (Pharmaceutical Production): Eurofarma is another major Brazilian pharmaceutical company with a strong performance in 2024, securing the second position in sales to pharmacies. They are involved in the development, production, and commercialization of a wide range of medicines. Their growth trajectory indicates a robust business strategy and market penetration.
  • Hypera Pharma (Pharmaceutical Production): Ranked third in sales to pharmacies in 2024, Hypera Pharma is a key national player known for its diversified portfolio, including a strong presence in over-the-counter (MIPs) and a focus on expanding into specialty medicines. Their strategy involves diversification to gain market share.
  • RD Saúde (Raia Drogasil) (Retail and Commercialization): RD Saúde is the undisputed leader in the Brazilian retail pharmacy sector, with the largest network of stores and the highest revenue among pharmacy chains. Their business model emphasizes extensive territorial coverage, a wide product mix (including non-medicines), and increasingly, offering health services within stores, positioning themselves as health hubs. They demonstrate high productivity per store and per employee.
  • Major Distributors (Distribution): While not a single entity, the collective group of major wholesale distributors is a critical component. They are responsible for a significant portion of the volume and value of medicines reaching the retail market. Their main activity is ensuring efficient logistics, storage, and timely delivery across the vast Brazilian territory, connecting manufacturers to numerous points of sale and healthcare facilities. Examples like Grupo Palmed and Sulmedic highlight the presence of both regional and specialized distributors.

Volumes and Sizes:

  • The Brazilian pharmaceutical market is among the top 10 globally.
  • The overall pharmaceutical sector in Brazil moved approximately R$ 220.9 billion in 2024, representing a 12.7% growth from the previous year. Another estimate places the sector revenue over US$ 20 billion in 2024, potentially growing to US$ 26 billion by 2028.
  • The retail pharmaceutical market specifically reached R$ 158.4 billion in sales in 2024.
  • In terms of volume, the retail sector commercialized 8.1 billion units in 2024, a 6.1% increase compared to 2023.
  • Distributors were responsible for 57% of the retail volume (4.6 billion units) and 55.7% of the retail value (R$ 88.3 billion) in 2024.
  • Brazil had 93,700 pharmacies and drugstores in operation in 2024.
  • The top 10 pharmaceutical companies by sales to pharmacies held 48.6% of the market share in 2024.
  • Grupo NC (EMS) led sales to pharmacies with R$ 26.4 billion in 2024. Specific revenue figures for other top companies in 2024 retail sales were not available in the provided sources, only their ranking.
  • The top 10 laboratories by Rx sales in Brazil in 2023 included companies like Novo Nordisk, Takeda, Bayer, Novartis, Aché, Sanofi, and AstraZeneca. AstraZeneca showed a significant 26.6% increase in Rx revenue in 2023, driven by specific medications.
  • The three largest pharmacy chain groups (RD Saúde, Grupo Pague Menos, Grupo DPSP) concentrate around 40% of the main consumers. The large networks associated with Abrafarma account for over 47% of the retail revenue with only about 12% of the total establishments. RD Saúde alone had a revenue of R$ 3.6 billion in 2023.

References:

  • Abradilan. Dez maiores farmacêuticas do Brasil detêm 48,6% das vendas. https://vertexaisearch.cloud.google.com/grounding-api-redirect/AWQVqAK4dBmW7IL9RJrghI81NrTydx17jDcvLPcJ4rnNRn2f5n8GkMkcFku27e0pt7zAEFjLiJqaY4vDTnyw0BSDp4BDXTX-8HtzLrfoLRx6vssa4XhvxFLdf1kLe4rqa3Hry-GwhRsD4GId0WAZJ2LjBMwewmueCX0nlRG2UtSnxK0xQDM38Z_dcEoRtcqly7wpDf2bEEQq
  • Abradilan. Dez maiores farmacêuticas detêm 48,6% das vendas. https://vertexaisearch.cloud.google.com/grounding-api-redirect/AWQVqALpXuNxLNuYpAUq48iyrcyWHkTee43sqtPbo5sKgazL_0uOyljDTRCA20arcXfsQkJYHlIuPwNOJg3jZVTbD-R3p4AVQuAUnr6LPsZOzTb_BMvq_xKG8mpXhhyTJdAMl1xnbkCfpigFP4VOzx4pu0KpSCRF92zXOLs4jHN9PKMaoOiEo-0RLXfJUkHIQc-DnT-xyvA=
  • Abradilan. Crescimento das grandes redes de farmácias. https://vertexaisearch.cloud.google.com/grounding-api-redirect/AWQVqAJQvM2Bbhx0gRiEaCgbjryC4a51OVqPyYh9AEXJmJnBtkvcO9voUj4vOBer-GpuM9d52e3lxpapdndt6uF-Yz_k2QJ7iN7ukVsS6SMJ4bCMOVLArW2Y28op7s2tRE0MG3yt0o65C0PWDBhNmKI7QorBJxkxUeQqIlkLrOkQTvtkZbNhAYQPHw==
  • Abradilan. Setor farmacêutico cresce 12,7% em 2024, mas reajuste autorizado gera dúvidas e impacto no bolso do consumidor. https://vertexaisearch.cloud.google.com/grounding-api-redirect/AWQVqAJ6oewzup0MipyduN_YHEGepVM7-62jACI8s2nBbIJ-3AJFMY1UNg9FFM-JBqiqymPaEx0GL1OYBsiSZ-Zvx0qQjNvrNEmPz6m4KI_YAzdvSIntrzqIr-xzlffWuKki22R_tebGxIYeTb97cOMG0IJQda_-wHafXM9xTPi-y8zpGCHXj2rJiIkV47b6J-1Ht50f1swI9KjvTqrm1mZwbHkyyZXp12cW4cNQDPAHL-0Th63snYfvWUVxIZ2DLayII8-E7XkktdOfsw==
  • Agência Gov. Nova Indústria Brasil contribuirá para fortalecer produção de medicamentos. https://vertexaisearch.cloud.google.com/grounding-api-redirect/AWQVqAK5Kv9aeoW7mQcz7FY1jkZ1INxL5cQgkt7AIc3-i4Ch4QDZqHqf2-sAy7fa5QYJkZHGB1YgUkuEF1MMt-B0El11vD9EwIfMrWeBZOeUZfjBC2VNU2BCVTA5cw8Dx8mlkRgoXbokOIlm1UAxOzkukZ2caTo-szPj2NOdJ16IzjQOruC0gmFuzq5VXWcuI8RhR1jXY3ML93Qn-8GLKcYV5uCIez_XaKylfOvUvTG7Fjo=
  • Anvisa. Anvisa divulga dados do anuário sobre a indústria farmacêutica no Brasil. https://vertexaisearch.cloud.google.com/grounding-api-redirect/AWQVqAI1R1mDDEsWkUAyXNIG3V3JR8uDNGaFC0EGZXsmnicqrgjVhLjUsjitLh7pJIjz4_iwiu_aCJRO3eVqoPUJgqGpzCYS42eJ4bbN0QulIjVkgLB0yVJd7J-RxPuCs3zP8zNyOTE_X-5vmD6s_stpzPHnic0rMGD3ARBKWdMhst8YndvQoqJPSkvyhRtsQbg5TutRP19f44t9nIyyVNClNfCTUOQUcFhdee_dr1FGxCMrfLV07N95SZpWrJ90ezY=
  • Anvisa. Aprovado novo marco regulatório de BPF. https://vertexaisearch.cloud.google.com/grounding-api-redirect/AWQVqAI9gDWl7qkGtIKzBl5OeE2gjax-wbsV6gSZtX0Q-9QnuBY0c-3HVVAbPpsmUG0BqPxSJC_9oj2TjGWvDZILZhZhn2K1URb1oXe_0uaU6_TyN_M-XQvbCBF-y5CG6om9qBi4Nf5NVI5PtvdA3SMLicxcwd7FO4C6np2Rqx1446cyD_0nlU_bsE2gjHHqoyjUUsbB05iWhWgBvn03boaPeORyOkXf7iQhL348ahmaLy_wUNndR1XSMFigwG2devY0m9uvgjQRsVOwOB7ubSMJs5ZZIw5nB7pIJ5kxOvXlHHBhTlWQUOTUhMvy8_056GAg1cwaffHcDKQma-dLjjo1ZwQ-U6Ymf-AoVpFu8J2TR9
  • BNDES. Cadeia farmacêutica no Brasil: avaliação preliminar e perspectivas. https://vertexaisearch.cloud.google.com/grounding-api-redirect/AWQVqAKpPq6Hc2123pZ1bGwbMmVaJWel4gqVfKerr8qqxAwLd0Mtt07BHKYqDRzM3jz-eWBoxnFsGSCn7Q_lc_J3wXtH5Nkpn3lucfeykmvUuqKnN37WOobBIjCorrVADwC3BzcgOJ-QUpswySDkiDyP6yCAfy6E5w7w6Uh4YiFaQrnbqUdJci2rQ-YuivTv7IZNDk3TqL-7n9eOyK2thF8e_xMAic8=
  • CDPI Pharma. O tamanho da indústria farmacêutica nacional. https://vertexaisearch.cloud.google.com/grounding-api-redirect/AWQVqAI6RO0SvLYlBz9Iw4WD228qTJUiXouKW-MSKs8qfdnBezT5pE3ovspu2i1pqoJoZzG5720LxBWKrqo7EfwcjItrP_MeGjVU7CaG4QNAXYgOcewXCD3tzoRls3qcXbusXdoJ6r3Im5D6lT9-KEE6v4iWaPcVHnCJku6v9Fpl8GXReJLrPWs1tg==
  • CDPI Pharma. O investimento da indústria farmacêutica em pesquisa e desenvolvimento. https://vertexaisearch.cloud.google.com/grounding-api-redirect/AWQVqAIOPI2aIWEOzjsR1K6-rAh1Hm2DPdVMdF_kNBLsfb3AAHDT7UH9m936C3zLVkxFJXvpZqGj1CbsDy8J04jQd3YE0jP7IdcG8cgBHvESA-TL7o8UAKGmJ5nR1-CBUOucQe_E6itidecJ0JB06UWKhDov1uWHtP9wQ60fci-Obr-UY-M_3RWWcaRxmvEBmdYNVNWpixpsBwBJ45W9fCL9WNk=
  • CFF Admin. Por que o Brasil não avança na pesquisa e desenvolvimento de ativos farmacêuticos?. https://vertexaisearch.cloud.google.com/grounding-api-redirect/AWQVqAKhmSIV-KbQjIEDsZeWVffd53eAxC7v4JJy00N3e-qRNNpYL52FinOeJxqgSJ-z3WthotUFATXtWFATeui1i7w4sS905K0fj3ZxCe9qB9zkzWIgc5Qyl2uYY33nTRjdLnvWV4paSs4zSBqoLA_vHbfmDakPN6eaGyOJd5x4ZNeCmMYlxJUxmm47t8vYKC2LK7D2PBhwFqVIDEZA
  • CNN Brasil. Brasil importa 90% da matéria-prima para a produção de medicamentos. https://vertexaisearch.cloud.google.com/grounding-api-redirect/AWQVqAJkEXBgRqERKM3OU_1a5P2V1bZL2YlQQkpi0NR3QpPWDTKCsWS6XYRohS5UlGSS-ROeAtK3rZKJA9rJbqXzq2cpVP1--_5IF4C7P9BfRm7pS1vh08F9uTrRyNkl36LxoLR4IoRPdvMN1eDexnFCcOAcJ4XsCEud98QONXeXR7cTH38qvWKn_ybIceqVFaztln4f2JV8W4RkH1IgJz4=
  • Dr. Fisiologia. Indústria farmacêutica brasileira e suas tendências (2025). https://vertexaisearch.cloud.google.com/grounding-api-redirect/AWQVqAKQMu9XsUuRgkirb0jpcJZmL3WYZ922MGauO9kxE34Zfp662VYuzCVFMkQ1WZSYOMyYE9PloY2nPyxsLE8d3Ks50aSaH_pd2dsu59Kti8O4MChE3SF8HByKohD9IIR1uC_gAS8X8s8nGXes3OyMbGqIIg6pPAr2ivb7UBCAXrOJ_4wGPmp5ASQ=
  • Faz Acontecer. Investimento em P&D pela indústria farmacêutica bate recorde em 2022. https://vertexaisearch.cloud.google.com/grounding-api-redirect/AWQVqALZynRIWGqCJ-wZgBo4zLFnzabvpqb0qsyvVQluWMsc_pae42RR1aGNaM9oxtCHyF-lFrxShFfjRYmkYIB6i7dZpCQk1M_s0vSkM59tXTPAw9rIlBtOsDRKkA4LUf6oAGaYlRdwx_WnSGmVBuVuYXyCEzhuHM4P_O0hz5HoH-WXnFXx4CYC75eCBGqKd4tezfvl7MGU8a5QgA==
  • Febrafar. Varejo farmacêutico: veja destaques de 2024 e expectativas para 2025. https://vertexaisearch.cloud.google.com/grounding-api-redirect/AWQVqAKM2-l05VCBsp7WQvPVjFuC3u6Jc0hcd0aTLW5mQVfaSl75mWVgEIxcZPq80Dv4ohIsFtH167y1h6qCcwp_IR44Q3w2cQfdMZLxP1rMMV-yMQUWmSW3fZRvrRR3uLLcIMJKgjCWvaPuiScFDNv4F1wr2K1ZkUHEXHiA1msHYAxkMXnmg16SmUOWirPA4ca2tVvEMA==
  • FIA. Indústria farmacêutica: características, setores e mercado de trabalho. https://vertexaisearch.cloud.google.com/grounding-api-redirect/AWQVqAKookK2CQWz2tEgTJ0j_F0pBsgoqtjkZX0ZeT5gsx-S0cNeEaXOzPrQ8CzvOORCTk59VD1Y2swU0eB35_1VxIkKGY5GWTN7yj_WuzWS7r2pmlNIlXvllByL0eEhzwBNV8JQgCCOog==
  • Grupo FarmaBrasil. Pesquisa, desenvolvimento e inovação no Setor Farmacêutico: o Brasil no cenário internacional. https://vertexaisearch.cloud.google.com/grounding-api-redirect/AWQVqALZ2BETI3jPiRqzuek8DKdowsfWRbliOaSPqQOExfaoUWoX-oTE_-mA7SZojjIWTDWbTVD7kRaB1thQrBExgHLcncmV9elcdjrLg1yLlFX6hsQY9vFjPgpGOrDU5MvDpdg2XvbpF7RS6YRjd9mFlekCm6MtGYTwTrTiQBNV3MwGFCkjnviVQHwlycEARbPKvR3LDkiTALdo3lOCt-uF7Z_JjC57zYUaVHWDz-N8n9YM_2bhbcXTbC-OcpnEspKK
  • Grupo Palmed. Distribuidoras de Medicamentos. https://vertexaisearch.cloud.google.com/grounding-api-redirect/AWQVqAK6c43iajOsA7zTZUdPy7RvC1sErJ8AuObgS20laAWZ-96gD7BlB_LnlIoR9lUwSS2RQuH9ls8OTSNpPBLxfwSfe_ON1LbzBnm494rI5LxdMPYjs-yp
  • ICTQ. 14 atualizações regulatórias para a Indústria Farmacêutica em 2018. https://vertexaisearch.cloud.google.com/grounding-api-redirect/AWQVqAKu-mC6S157t6K7EBEnAiOLaLWmM7MontA5Td_VmJnnaOBj5ddWHZNxAxNncFhCcWfwwnkeOjVwmrMtKBwWYokC7yUGoDplUf8cGH5lXeWIHQJraSRbSZksTaUagcFWXOFyIY619tF902odELU0_olAjJfqGkF21xuoJNulK0OiExw8hsHNgrEmBqghNDvjMe1DQa4S05RCcM3COzqtLF1sQ_bMurUbAQ==
  • ICTQ. Os modelos de negócios farmacêuticos. https://vertexaisearch.cloud.google.com/grounding-api-redirect/AWQVqAIDIs1EXmr0VX2UaHFTyFmlDgRMdb39NLBfcqSiBZgfflx7WaYivX5C0haEQxlpCAPgoymRl-mQ5ir_A5uk9wuB49rKMOXJADTn3ylJIUADw17Yrat__aoZrwv7ZNkCHbkwKKh9zYe_YthUi4B1YgbITFRr6sCoOqTBKe-iSPdejd9DwzQe
  • ICTQ. Anvisa - Confira as principais atualizações regulatórias que ocorreram nos últimos seis meses. https://vertexaisearch.cloud.google.com/grounding-api-redirect/AWQVqALPVMuXn_y5xwz3c2_zaD4ZbEZQGF5x6WRcZ3wZ49Nq5JVlaw_MskHDuOx8DJWW_qzM9WxZaReHgdEEa2jawEf4lOG0LaVWOJMNzZ_AcMRwgwE5Q_P4K2dHnAZAqxZnf1FpF5cKMhuoRZclr_JTES8kpqKRGnPN_AtLreKWnuh2JtbfYGkkafG6kxuyUx13GbZ1CkbyNfecMRTETLI4zT9N9PDRXq-zZboNbHSsnAVOgLBRB8QzHPpbR5uI8zUl787_
  • InvesteSP. Setor farmacêutico é o que mais investe em pesquisa e desenvolvimento. https://vertexaisearch.cloud.google.com/grounding-api-redirect/AWQVqAKI7DFTS-I3JlUk2dRk4u3WTrV3k-2_qAG6X_cwCznMOB8zdDAtEg0jCLy-sTtqbldWP1SzkycYrCyWK6J8f-ERZZWfjC2sy6r4OLRNCo8rJB7geBaiji78G4K9tp9yPlHV1kCkhMSUbfh3ycnGiDdN4UHIO7iSu_xiK_mhnLAvRd0xDLVo4gFDM26iD5IsLhtor560Knlju7S1usuQwdq57Ao=
  • MOOC Fiocruz. Indústria Farmacêutica no Brasil: um breve panorama. https://vertexaisearch.cloud.google.com/grounding-api-redirect/AWQVqAKfeo_M1IRzxZdKgzm61fIQTNHqHxNKQNCjFPmoxYlzxKnSUj_79D0-tAke-J5vrhSFno-gPNlPw5PnM-OegK1wzDYGs7wtQJTQRF9KlbsCbMrDo0kPMzxdzVEtFkGwC4z39A3sHfMc2_eNWJxxJVRDo-CLQtSWOKcxQjNq3vaqNrRG55vCfz6TVC_du-1WzmM3C1XwdqcME9334I_kXb486WeRO895FYK5Rk4=
  • MOOC Fiocruz. Estágios da produção de medicamentos. https://vertexaisearch.cloud.google.com/grounding-api-redirect/AWQVqAJBpCUNWA2GIdEK4B74S7G_SkSCnouS08rcWI2fCEYd9EFvOl25auLohQ_dTVbDFcG7_Me8Xxoy6UrthMMWSxiba8CUpiP7LEZMhCFHhh8ZqEZOZn20R6b5x-ttrbd9Q02cOnVtKsX3XiFoPzrnyyB0mZ3TW4WYUjm8531XvLq6Hs-rQOw0fP_sYj7Hv8QcTEyfkA-EahtkslEV15s=
  • Medicina SA. 90% dos brasileiros preferem a produção de medicamentos e insumos no país. https://vertexaisearch.cloud.google.com/grounding-api-redirect/AWQVqALRfFyn4myA06BTLPLsw4ZjKhLysuixsN-x1uPBY_jpKFarhXPXVJ-iX6JaDKpq-MZkkqQaA5YzvAIovU8p1wkKq1bItWutaZl7bXbQCu9tvDkCkkCeWdUv0hZDIQiLA3dyPInTBWg=
  • Medicina SA. Três grandes grupos de redes de farmácias concentram 40% do mercado no Brasil. https://vertexaisearch.cloud.google.com/grounding-api-redirect/AWQVqALt0gL0jgjYp84ICSxVmPrid3Wljdfvx8RZrFI_fb8dZMYIKdXH7lkeRJQVVr03mtdGz_WnJpH0RI6Wke_6kxcSUsyIYBsHKG7nE1Z7Jq6OSlIUKn42uSGgd2bE59Gdl8-w1YAgc_KJdBS41WXI5uOYkDUWCEIbAfhD_lgUz2lfakMFunYptYP4hul_fW7zkMhB1JM2fTR6h44xZkMtJv6c6ZyDp3Jn
  • Medicina SA. Três grandes grupos de redes de farmácias concentram 40% do mercado no Brasil. https://vertexaisearch.cloud.google.com/grounding-api-redirect/AWQVqAIk34XBoqasSLvxVKCo9esjEaCOKMUG-xT1BYilO8bi3GrTiQUpYtshRQCKMo53MjQbGvLPD50Q2OAp8QI-CUQpkclD8dGGnTdYG9JdOKStsVMMUiW2tl1rPWdIFGw1M24=
  • Medicina SA. Varejo farmacêutico cresce 11% e movimenta R$ 158,4 bilhões em 2024. https://vertexaisearch.cloud.google.com/grounding-api-redirect/AWQVqAI08jkENfgmtq0pdfAglEEqmva87EFi02Nnl6XzbaLvJuSf0sVr06tzIn-3e-fNYZgWmSNQEzdNQaCB6NXpQD-JdLYHBjRVWsurGaxskgHmRoGMefB2-vT9bzuUwcAwYdPCgL0Q
  • Natcofarma. Varejo farmacêutico: Confira as principais tendências. https://vertexaisearch.cloud.google.com/grounding-api-redirect/AWQVqAKRwEohyEUDL_ina09Sn7GcxqmWD6MHTMVYYKSvu8VeVXzmNLqVNUYa3UZvFy3ahDGYzPGFu3K8vKFzGGcE7YSgVLg-FqnfRvFeJjwtrXVA7nUdQ5Qv8zDnYxI7FbNj7wpJqaT726EZtC57Q1Y=
  • Omni Hospitalar. Como funciona o processo de distribuição de medicamentos?. https://vertexaisearch.google.com/grounding-api-redirect/AWQVqAIVmYqqNGSA0N8hZdyJkWIGCnBPAqD8Vlg9_03oIRZNfhX1GD96pQq2B0S0AnSMF-cpGbHDNNQHRi29_QflBjIy-Iut00FV12RLnC7iNmxtDfDWY-7DrpVc3ukmFHJeVpjrW0SgC-8QzhYEd6THPLifn_crM3LZeybcqddfx_UM5yDVQfP-gfapEIWAUD8UlF_6QTwCUq0C6g==
  • Panorama Farmacêutico. Dez maiores laboratórios do Brasil têm 55% do mercado. https://vertexaisearch.cloud.google.com/grounding-api-redirect/AWQVqAJdgOgJGT-yf6Xs8QSu2zs9sQJmCXVtGknZ-HFxiDNByocwokIi8kRjvxbYiHuUkkpCMs2onZLzrxjYfKyd4xmMna3UvFh3-iG3xsANWmt4NElBiepjjKSnmEdSLc2FXhunY7-f0EfzOSKtf_ALZ1Mrsj5t8Wa58iR6__yDG3WI1Q==
  • Quais são as maiores empresas farmacêuticas do Brasil e do mundo?. https://vertexaisearch.cloud.google.com/grounding-api-redirect/AWQVqAISdRInNTPYkHBc1ENbUUEeuHsGOS9aVdkFT289OTt9s3T9L7d_21umpDEheBjOQVsHVwWn2FKk1SEUNZbxUKkCPcJiBIFG3xmgxGAZKHRaPEm4rLLqmlviYDi-N_wnO2FggQu1Cn2RM7fC-RCTtFQ0jofoeanZ2x8LjWJIBw4Btu3I
  • Qualifica. Legislação Sanitária para Indústria Farmacêutica: o que mudou?. https://vertexaisearch.cloud.google.com/grounding-api-redirect/AWQVqAKkkWdCIXg3z4ctwDF2MvMZg_JF_6yH1MaKyZI6GdhxJWYRYKBSuYOm-WGxSWST1Psp5iLZv7X37SlELXRyGDPFNGOYZ1KgMaAme8mnleiyEIctsAGsb4P9hQ1fDANh0WVDgr_xNayG6EtFZWdwp9exWgF_IiWuKPkVIVqYdZg3E0ngYqUcpwuWP5Md
  • Sebrae. Como montar uma distribuidora de medicamentos. https://vertexaisearch.cloud.google.com/grounding-api-redirect/AWQVqAKeBpZYdXFy2M6K8Yw4QOU-3kS2FqUWGvYQjEB-2ZIopTJAAWil0XVjMUD7E71HPi6Z8AQkRdAVolmpPsT4BgU5L82UoLrhL55qI8RQufzMpvBmlN6i07TES3ACCSkkab1fs1awKM9_AtSc3NZAWuHsFEDQxK484O3LRCQ2a6LGrP9t04OJ7gARu0tuuZqcUl-jkrj77JtN1GvL-j7OQog-vbc_UAkNcbNUK0OdkRDFUDpte2N7zjnfxPKnvRc=
  • Sotequi Vedações Industriais. Segmento farmaceutica. https://vertexaisearch.cloud.google.com/grounding-api-redirect/AWQVqAKt7SandpxoK0S5tYvVjF3TcXNmOvo0ls0VGDc6RlcEDU4QSSmmGNMTxJx7M9tU_GyP6dymxwZz0Ga9WrmWNQIGg8gUUYpAhUZreQTH-g1JWXlAcIBfXcJ4Jnov0E9jKI6g8g==
  • Sulmedic. Distribuição de Medicamentos Hospitalares. https://vertexaisearch.google.com/grounding-api-redirect/AWQVqALa-mtTu9ZY8V6n-87tWrt5JhpJDV0SBDCKphNSNSdCgoYMA4qkUfpXesA9o7nBAzs49RdrhTsevVf3T6Q2ccOXiG21ULJ_1YLZew8L0MMC
  • Os Tipos de Empresas Farmacêuticas :: Gestão Farmacêutica. https://vertexaisearch.cloud.google.com/grounding-api-redirect/AWQVqAKvcFHq21Ls0RtgnofCCBYa_SKSM6eqf_tOFzpDJ-C3CdPfDSZRVSDOqwxKQznJp_yCd61MWjoHwcl_Q0sRWDKkVepGpHkTD80MQRMtBFABeEQ4yysc0kxbu5l_YB6APKWPSb4jUdHB0TT9ESsUSTqLNRxKTjUTrPRU
  • VEJA. 90% dos brasileiros dizem que produção nacional de remédios deve aumentar. https://vertexaisearch.cloud.google.com/grounding-api-redirect/AWQVqAKFX7A5G6MJJTxDYG6-9n530mtZYiAJRnWPXkvhWFuPgQby1S-W35pg4ld5tPb3TfLx7uVazsnt6Ck0o5FJc4Ac7usRHUR0K4cWbEIUhyjA9igkRwW34jZDTFm_Ok5hsZc0uryiyawYQXKOX4ntXME0_mu82GHx-MmKZiqQ-Rp0XcsdaPI-xEcd3zSqBrp48NIBzKhkAef4aW3JuxcnWg==
  • VEJA. Varejo farmacêutico cresce 11% e movimenta R$ 158,4 bi em 2024. https://vertexaisearch.cloud.google.com/grounding-api-redirect/AWQVqAK9_96l4BPgvD9CwbNugxCIuz1QVJhf67tbK4Nwzk02qecdzNfxJvkJo8yxxMbYLKvgyfmNoIf16ThHVqruJCcOCFWIPUkf3Kz0fL9_iUm0u-lMa4VfDF4oNezCjEnM79vHNSLnjZjtPJPvbFYYw-jQ517bVz5MlgY96MXeHG9QV8psa-vIDG1Wc-LjuZwHIy74Z-fbBSQ1OHQi
  • Vernalha Pereira. Novas regras da Anvisa e o seu impacto no registro de medicamentos para a indústria farmacêutica. https://vertexaisearch.cloud.google.com/grounding-api-redirect/AWQVqAJhK-uN98bYJ-XhH7eb-JJZz_U-CC7BXj8la4seI-8MJSUyr0S5yEjS0_8IdDgPev_ObsYyv2vLydzivo9LrAqAxR8Q4CKfA-jXyPO5YsblAM8RjfUirBtNxbPeYDyae-PGd95kx5lziWSDSe587XnoeYOH243EkrfuAY3IFYZtms2OcLePx_IrfGrkhmS69CoMwx5r3NdIWAEkS2qLZs2Noqqbhkt9tmofKO2d0Yuu7KCXocni8yU